ExpreS2ion Biotech Holding AB

ST:EXPRS2 Sweden Biotechnology
Market Cap
$1.58 Million
Skr17.76 Million SEK
Market Cap Rank
#35685 Global
#575 in Sweden
Share Price
Skr5.03
Change (1 day)
-0.98%
52-Week Range
Skr5.03 - Skr28.05
All Time High
Skr1818.80
Categories
Companies in Sweden Biotechnology
About

ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more

ExpreS2ion Biotech Holding AB (EXPRS2) - Net Assets

Latest net assets as of December 2025: Skr35.69 Million SEK

Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) has net assets worth Skr35.69 Million SEK as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr65.11 Million) and total liabilities (Skr29.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr35.69 Million
% of Total Assets 54.81%
Annual Growth Rate 27.51%
5-Year Change -74.57%
10-Year Change 177.07%
Growth Volatility 109.89

ExpreS2ion Biotech Holding AB - Net Assets Trend (2013–2025)

This chart illustrates how ExpreS2ion Biotech Holding AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for ExpreS2ion Biotech Holding AB (2013–2025)

The table below shows the annual net assets of ExpreS2ion Biotech Holding AB from 2013 to 2025.

Year Net Assets Change
2025-12-31 Skr35.69 Million -44.60%
2024-12-31 Skr64.42 Million -1.44%
2023-12-31 Skr65.36 Million -36.74%
2022-12-31 Skr103.33 Million -26.38%
2021-12-31 Skr140.35 Million +48.44%
2020-12-31 Skr94.55 Million +8862.56%
2019-12-31 Skr-1.08 Million -113.00%
2018-12-31 Skr8.30 Million +23.22%
2017-12-31 Skr6.74 Million -47.69%
2016-12-31 Skr12.88 Million +314.38%
2015-12-31 Skr-6.01 Million -355.94%
2014-12-31 Skr2.35 Million +21.56%
2013-12-31 Skr1.93 Million --

Equity Component Analysis

This analysis shows how different components contribute to ExpreS2ion Biotech Holding AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock Skr15.69 Million 43.97%
Other Comprehensive Income Skr-187.08 Million -524.24%
Other Components Skr207.08 Million 580.28%
Total Equity Skr35.69 Million 100.00%

ExpreS2ion Biotech Holding AB Competitors by Market Cap

The table below lists competitors of ExpreS2ion Biotech Holding AB ranked by their market capitalization.

Company Market Cap
IMCO Industries Ltd
TA:IMCO
 		$1.17 Million
Gold Ent Group New
PINK:GEGP
 		$1.17 Million
Rolling Optics Holding AB (publ)
ST:RO
 		$1.17 Million
Dharani Sugars&Chemicals Limited
NSE:DHARSUGAR
 		$1.18 Million
Lamar Advertising Company (REIT)
MU:6LA
 		$1.17 Million
Lifeclean International AB
ST:LCLEAN
 		$1.17 Million
Manchester Building Society 6.75% PIBS
LSE:MBSP
 		$1.17 Million
EIFFAGE
BE:EF3
 		$1.17 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ExpreS2ion Biotech Holding AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 64,799,000 to 35,686,000, a change of -29,113,000 (-44.9%).
  • Net loss of 38,085,000 reduced equity.
  • Share repurchases of 12,096,000 reduced equity.
  • New share issuances of 12,096,000 increased equity.
  • Other comprehensive income increased equity by 29,553,000.
  • Other factors decreased equity by 20,581,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr-38.09 Million -106.72%
Share Repurchases Skr12.10 Million -33.9%
Share Issuances Skr12.10 Million +33.9%
Other Comprehensive Income Skr29.55 Million +82.81%
Other Changes Skr-20.58 Million -57.67%
Total Change Skr- -44.93%

Book Value vs Market Value Analysis

This analysis compares ExpreS2ion Biotech Holding AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.40x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-12-31 Skr10.65 Skr5.03 x
2014-12-31 Skr12.95 Skr5.03 x
2015-12-31 Skr-33.13 Skr5.03 x
2016-12-31 Skr45.36 Skr5.03 x
2017-12-31 Skr0.55 Skr5.03 x
2018-12-31 Skr0.56 Skr5.03 x
2019-12-31 Skr-0.07 Skr5.03 x
2020-12-31 Skr4.94 Skr5.03 x
2021-12-31 Skr4.35 Skr5.03 x
2022-12-31 Skr109.52 Skr5.03 x
2023-12-31 Skr56.66 Skr5.03 x
2024-12-31 Skr24.96 Skr5.03 x
2025-12-31 Skr12.54 Skr5.03 x

Capital Efficiency Dashboard

This dashboard shows how efficiently ExpreS2ion Biotech Holding AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -106.72%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1041.43%
  • • Asset Turnover: 0.06x
  • • Equity Multiplier: 1.82x
  • Recent ROE (-106.72%) is below the historical average (-65.32%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2013 35.66% 10.33% 1.62x 2.13x Skr495.54K
2014 11.90% 4.22% 1.21x 2.34x Skr44.56K
2015 0.00% 0.00% 0.00x 0.00x Skr-7.84 Million
2016 -66.29% -183.53% 0.19x 1.91x Skr-9.83 Million
2017 -145.98% -100.41% 0.57x 2.56x Skr-10.51 Million
2018 -202.65% -189.69% 0.42x 2.52x Skr-17.65 Million
2019 0.00% -120.78% 0.74x 0.00x Skr-16.60 Million
2020 -33.54% -603.02% 0.04x 1.26x Skr-41.17 Million
2021 -31.30% -359.04% 0.08x 1.08x Skr-57.96 Million
2022 -114.79% -2331.99% 0.04x 1.33x Skr-128.94 Million
2023 -139.83% -1296.47% 0.09x 1.20x Skr-97.94 Million
2024 -55.62% -1196.08% 0.03x 1.61x Skr-42.52 Million
2025 -106.72% -1041.43% 0.06x 1.82x Skr-41.65 Million

Industry Comparison

This section compares ExpreS2ion Biotech Holding AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $106,934,177
  • Average return on equity (ROE) among peers: -113.07%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
ExpreS2ion Biotech Holding AB (EXPRS2) Skr35.69 Million 35.66% 0.82x $1.17 Million
2cureX AB (2CUREX) $43.03 Million -69.18% 0.11x $1.39 Million
Abliva AB (ABLI) $70.72 Million -135.06% 0.24x $46.60 Million
Ascelia Pharma AB (publ) (ACE) $74.33 Million -147.03% 0.17x $25.35 Million
AcouSort AB (ACOU) $33.02 Million -37.49% 0.11x $4.79 Million
Active Biotech AB (ACTI) $646.03 Million 0.00% 0.35x $3.42 Million
Alzinova AB (ALZ) $59.11 Million -10.49% 0.07x $3.99 Million
AlzeCure Pharma (ALZCUR) $32.97 Million -235.89% 0.38x $12.21 Million
Annexin Pharmaceuticals AB (ANNX) $18.81 Million -234.16% 0.42x $4.76 Million
Alligator Bioscience AB (ATORX) $68.52 Million -112.06% 0.43x $757.29K
Biosergen AS (BIOSGN) $22.79 Million -149.37% 0.48x $2.84 Million